Entries |
Document | Title | Date |
20080261950 | Compounds that inhibit cholinesterase - Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The compounds of the invention are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine. | 10-23-2008 |
20080261951 | Condensed azepines as vasopressin agonists - This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V | 10-23-2008 |
20080275023 | N-Hydroxyamides Omege-Substituted with Tricyclic Groups as Histone Deacetylase Inhibitors, Their Preparation and Use in Pharmaceutical Formulations - New N-hydroxyamides of n-alkyl carboxylic acids omega substituted with suitable tricyclic systems characterised by a central 7-membered ring, having activity as inhibitors of histone deacetylase (HDAC). | 11-06-2008 |
20090221552 | Methods for the Treatment of ADHD and Related Disorders - The invention features methods, compositions, and kits for the treatment of attention deficit hyperactivity disorder and related behavioral disorders by administering an organic cation 3 (hOCT3) inhibitor. | 09-03-2009 |
20090298809 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | 12-03-2009 |
20100227850 | METHODS FOR PREVENTING AND TREATING MICROBIAL INFECTIONS BY MODULATING TRANSCRIPTION FACTORS - The current invention is based, inter alia, on the finding that the transcription factor MarA, and homologues of MarA, e.g., Rob and SoxS, are virulence factors. Accordingly, the invention discloses methods for screening compounds for their ability to modulate these virulence factors. The invention further describes methods for treating and preventing bacterial infections by modulating the expression and/or activity of transcription factors. In addition, the invention provides a method for identifying other virulence factors. | 09-09-2010 |
20100267690 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS - Guanidine derivatives having a condensed tricyclic ring of formula 1: | 10-21-2010 |
20100273773 | DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS - The present invention is related to novel tricyclic compounds of formula (I) having TRPA1 receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use as pharmacological tools, or as irritant incapacitants, or in the treatment of diseases linked to the modulation of the TRPA1 receptors in animals, in particular humans. | 10-28-2010 |
20100305094 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA - Compounds of formula 1: | 12-02-2010 |
20110092483 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES - A kit and a method for identifying compounds having anti-prion activity are provided. The kit comprises a yeast of phenotype [PSI+]; an antibiogram; and a prion curing agent in a sub-effective dose, wherein the yeast has the adel-14 allele of the ADE1 gene and an inactivated ERG6 gene. Compounds and pharmaceutical compositions having anti-prion activity are also provided, which are useful for treating various neurodegenerative diseases, including polyglutamines expansion associated diseases; Huntington's disease; Kennedy disease; amyotrophic lateral sclerosis; cerebellous autosomic ataxies; dentalorubral-pallidoluysian atrophy; and spino-bulbar amyotrophy. | 04-21-2011 |
20110112069 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES - The specification describes the use of selected purine derivatives for the treatment of hyperproliferative diseases. | 05-12-2011 |
20110136784 | Method of Treating Anxiety Disorders - A method of treating at least one symptom or condition associated with but not limited to: Anxiety Disorders including but not limited to Panic Disorder Without Agoraphobia, Panic Disorder With Agoraphobia, Agoraphobia Without History of Panic Disorder, Specific Phobia, Social Phobia, Obsessive-Compulsive Disorder, Postaumatic Stress Disorder, Acute Stress Disorder, Generalized Anxiety Disorder and Generalized Anxiety Disorder Due to a General Medical Condition comprising administering an effective amount of Formula I | 06-09-2011 |
20110195950 | Organic Compounds - The invention relates to compound of the formula I | 08-11-2011 |
20140179678 | METHODS OF TARGETED TREATMENT OF FRONTOTEMPORAL LOBAR DEGENERATION - The present invention provides targeted treatment to subjects suffering from Frontotemporal lobar degeneration through use of FTLD targeted agents, as described in the present invention. In particular, the FTLD targeted agents provided herein demonstrate high brain penetration, which decreases risk issues associated with peripheral administration. Furthermore, the FTLD targeted agents of the present invention, when administered to a subject selected for treatment based on the results of a FTLD diagnostic assay, offer targeted treatment of FTLD. | 06-26-2014 |
20160108022 | TRIAZOLE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS - The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of Aβ-related diseases. | 04-21-2016 |
20160136180 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES - The invention is directed to the use of selected purine derivatives for the treatment of hyperproliferative diseases. | 05-19-2016 |